JEIL PHARMA HOLDINGS INC.

As of June 30, 2026, JEIL PHARMA HOLDINGS INC. carries a market capitalization of 96.71B, placing it among publicly traded companies globally. Its enterprise value stands at 350.14B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, JEIL PHARMA HOLDINGS INC. has 15.35M shares outstanding.

As of June 30, 2026, JEIL PHARMA HOLDINGS INC. trades at a trailing price-to-earnings ratio of 11.47. The price-to-sales ratio is 0.15, and the price-to-book ratio stands at 0.31.

As of June 30, 2026, JEIL PHARMA HOLDINGS INC. trades at an EV/EBITDA multiple of 10.42 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.55 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 19.18 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 350.14B versus a market cap of 96.71B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, JEIL PHARMA HOLDINGS INC. maintains a current ratio of 1.20, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 39.25, indicating elevated leverage, while an interest coverage ratio of 4.54 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, JEIL PHARMA HOLDINGS INC. posted a return on equity (ROE) of 2.70, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 0.97, measuring how efficiently the asset base is converted into earnings. The company generates approximately 16.18B in revenue per employee across its workforce of 39.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.26 indicates how many times JEIL PHARMA HOLDINGS INC. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, JEIL PHARMA HOLDINGS INC. recorded an income tax benefit of -759.63M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 24.66B, leaving 8.43B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, JEIL PHARMA HOLDINGS INC.'s stock has declined approximately 12.52% over the past 52 weeks. The 50-day moving average sits at 7,527.60, while the 200-day moving average is 7,849.85.

Over the twelve months ended June 30, 2026, JEIL PHARMA HOLDINGS INC. generated 630.89B in revenue and converted that into 8.43B in net income, yielding earnings per share of 1,656.00. EBITDA reached 33.60B, while operating income came in at 18.61B.

As of June 30, 2026, JEIL PHARMA HOLDINGS INC. holds 87.50B in cash and equivalents against 184.74B in total debt, resulting in a net debt position of 120.61B. Total book value stands at 314.47B, with working capital of 66.07B providing operational flexibility.

JEIL PHARMA HOLDINGS INC. produced 11.86B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -14.49B in capital expenditures, free cash flow totaled -2.63B - equivalent to -171.08 per share.

Over the twelve months ended June 30, 2026, JEIL PHARMA HOLDINGS INC. posted a gross margin of 40.69, reflecting its pricing power and cost economics. The operating margin of 2.95 and net profit margin of 1.34 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, JEIL PHARMA HOLDINGS INC. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -2.72: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -16.83, meaning JEIL PHARMA HOLDINGS INC. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

JEIL PHARMA HOLDINGS INC.'s most recent stock split took place on July 17, 2017 with a 250:73 split ratio.

As of June 30, 2026, JEIL PHARMA HOLDINGS INC. has an Altman Z-Score of 1.07, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.